Richard Barker has over 40 years of experience in healthcare and life sciences and is a passionate leader, advisor, speaker, and author. He focuses on the intersection of AI, precision medicine, and longevity science, with a mission to advance personalized, preventive medicine and extend healthy lifespan worldwide. He is the Founding Director of Metadvice, a company leveraging AI to provide personalized health advice and guidance. Richard also advises and supports life science enterprises on strategy, M&A, business development, and innovation to address the future challenges of healthcare. His senior roles at Celgene, ABPI, IBM, Chiron, and other organizations have enabled him to bridge pharmaceuticals, diagnostics, and medical informatics in the era of P4 medicine.

David Wortley is a globally recognized motivational speaker, innovator, and thought leader at the intersection of technology, health, and human potential. As CEO and Founder of 360in360 Immersive Experiences, he crafts transformative narratives that inspire audiences to embrace digital tools for personal growth and societal impact. With a pioneering career spanning over three decades, David has championed the use of immersive technologies, gamification, and digital medicine to address pressing challenges in healthcare, education, and the environment. His leadership roles include Vice President of the International Society of Digital Medicine (ISDM) and Founding Director of the Serious Games Institute at Coventry University, where he advanced virtual learning environments and augmented reality applications.

Sandra Carrillo, MD, is a globally recognized physician specializing in medical cannabis, with extensive experience as a clinician, educator, and policy advisor. Based in Medellín, Colombia, Dr. Carrillo is the Co-Founder and Medical Director of Medicann IPS Medical Cannabis Clinics and serves as President of the Colombian Medical Cannabis Association. She is an influential international speaker, scientific board member, and university lecturer, dedicated to advancing cannabinoid medicine through evidence-based education, research, and advocacy. Dr. Carrillo actively collaborates with leading organizations and journals worldwide, shaping medical cannabis policy and clinical practice to improve patient care and health outcomes.

Denise Marie Hradecky, LL.M., MSc, B.H., is a healthcare strategist and international healthcare expert focused on transparent, safe AI adoption in hospital systems. She has led hospital operations, lectures in health law, hospital organization and management, and advises international health-system reforms. Her recent book, Transparency in Healthcare: Methodical Approaches for Decision-Making (written in German; Springer, 2025), underpins her governance approach to clinical AI and digital health.

Tom Lawry is a leading AI transformation advisor to health and medical leaders around the world, a top keynote speaker, and best-selling author of Hacking Healthcare – How AI and the Intelligent Health Revolution Will Reboot an Ailing System. He’s the Managing Director of Second Century Tech and a former Microsoft exec who served as National Director for AI for Health and Life Sciences, Director of Worldwide Health, and Director of Organizational Performance for the company’s first health incubator. Before Microsoft, Tom was a Senior Director at GE Healthcare, the founder of two venture-backed healthcare software companies, a health system executive, and board member. Tom’s work has been featured in Forbes, CEO Magazine, Harvard Business Review, CNET, Inside Precision Medicine, South China Morning Post and numerous podcasts and media outlets.

Jurgen has 20 years of experience in building complex solutions leveraging advanced analytics, data science, database design, architecture and other cutting-edge technologies. Working in the AI industry since the mid-1990s, Juergen have built solutions for various industries and leveraged various methods over time. He joined Schneider Electric in 2022 as Vice President, AI Strategy & Innovation. His focus is to produce industry grade solutions, translating the combination of core algorithms, robotic, cybernetics and human intelligence. Previously, he worked as Senior Data Science Executive in Accenture and hold various roles related to AI and data. He holds a PhD degree in Business intelligence and new marketing methods from The Philipp University of Marburg, MBA in Executive General Management and MA in Applied Computer, bioinformatics and cybernetic from Paris Lodron Universität Salzburg.

Dr. Ed Esplin is a physician scientist board certified in clinical genetics and internal medicine with a focus on using comprehensive germline and solid-tumor somatic genomic information to provide patients with cancer, cardiomyopathy, epilepsy and other rare diseases access to precision therapies and access to clinical trials to improve care for patients, and genomic screening to identify modifiable genetic disease risks in healthy individuals. Medical Officer at Invitae for 10 years, he currently leads clinical trials and research at Labcorp Genetics (formerly Invitae) including the INTERCEPT trial with Dr. Jewel Samadder at the Mayo Clinic; the PROCLAIM trial in prostate cancer with Dr. Neal Shore; the Universal Germline Testing in the Community trial (UNITY, NCT05416710) with Dr. Kashyap Patel; and Labcorp Genetics collaboration with the eMERGE IV Consortium evaluating the clinical utility of genomic screening in healthy individuals. Dr. Esplin completed the MSTP program at UT Southwestern obtaining his MD and PhD in genetics, completed internal medicine residency training and served as an Assistant Professor of Internal Medicine at UT Southwestern. He subsequently completed clinical genetics training at Stanford University followed by an NIH-funded Tashia and John Morgridge Endowed Postdoctoral Fellowship with Mike Snyder in the Stanford Department of Genetics, where he maintains an academic appointment and is a consulting investigator for the Stanford Pre-Cancer Atlas as part of the NIH Human Tumor Atlas Network (HTAN). He serves on the ACMG Therapeutics Committee and is a fellow of the American College of Medical Genetics and Genomics (ACMG), the Collaborative Group of the Americas for Inherited Gastrointestinal Cancer (CGA-IGC) and the American College of Physicians (ACP).

Professor Dr. Mohammad Kamil, M.Sc.; M.Phil.; Ph.D.; D.Sc.; Chartered Chemist(U.K.) and Fellow Royal Society of Chemistry (London), worked in various capacities, as In-charge –of the Drug Standardization lab. (RRIUM-Aligarh) CCRUM, Ministry of Health -India, Associate Professor at Hamdard University, India; Professor & Head Department of Pharmacognostic Science, Zayed Complex for Herbal Research & Traditional. Medicine(ZCHRTM), Ministry of Health, UAE (1996 2010); Head TCAM Research at ZCHRTM, Department of Health(DOH)Abu Dhabi (2010-2020). Focal Point of WHO Collaborative Sheikh Zayed Research Centre, Abu Dhabi for 8 consecutive years; a recipient of the First Sheikh Zayed International TCAM Award in Herbal Research (2020) presently working as Director General, Lotus Holistic Healthcare Institute, Abu Dhabi, UAE since 2021; Secretary General & Head, Scientific Committee for Sheikh Zayed International TCAM Awards International Awards.